IGF-1 LR3
Research OnlyAlso known as: Long R3 IGF-1, LR3-IGF-1, Insulin-like Growth Factor 1 Long R3
A modified form of IGF-1 with an extended half-life due to reduced binding protein affinity. Used primarily in research for muscle growth and metabolic effects. Not approved for human use; significant safety concerns exist.
Research Statistics
Research-grade IGF-1 analog with a small human dataset; IGF-1R mechanism is well-established from natural IGF-1 studies but LR3 modification lacks independent clinical validation.
Research Dossier
Overview
What is IGF-1 LR3 and what does the research say?
Mechanism of Action
IGF-1 LR3 is a modified form of insulin-like growth factor 1, engineered to resist binding to IGF-binding proteins. This modification dramatically extends its biological half-life from minutes to hours while maintaining full receptor activity.
How It Works (Simplified)
IGF-1 LR3 drives muscle growth through four key mechanisms:
Activates PI3K/Akt/mTORC1 pathway, directly stimulating ribosomal protein synthesis and muscle fiber hypertrophy.
Inhibits FOXO transcription factors, suppressing muscle breakdown genes MuRF1 and atrogin-1.
Promotes satellite cell proliferation and myoblast differentiation, supporting muscle fiber repair and regeneration.
Stimulates GLUT4 translocation, enhancing glucose transport into muscle cells for energy and glycogen synthesis.
Scientific Pathways
PI3K/Akt/mTOR Pathway (Protein Synthesis)
IGF-1 LR3 → IGF-1R binding → IRS-1 phosphorylation → PI3K → Akt
↓
mTORC1 activation + FOXO inhibition
↓
Protein synthesis + Reduced degradationExtended Half-Life Mechanism (Key Modification)
Native IGF-1 → IGFBP binding (>99%) → Sequestration → 12-15 min half-life
IGF-1 LR3 → Arg3 + N-terminal extension → <1% IGFBP binding → 20-30 hr half-lifeKey Research: Francis GL et al. (1992) first characterized LR3-IGF-1 structure and demonstrated reduced IGFBP binding. PMID:1281011
Important Limitations
- No randomized controlled trials in healthy adults for muscle building
- Significant hypoglycemia risk due to insulin-like receptor activity
- Cancer promotion concerns - IGF-1 signaling is mitogenic and anti-apoptotic
- Long-term safety data is absent - most evidence is preclinical
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
IGF-1 LR3's extended half-life (20-30 hours vs 12-15 minutes for native IGF-1) means effects persist longer per dose. Hypoglycemia risk exists within hours of administration.
Animal studies typically used treatment periods of weeks. Muscle protein synthesis increases may be detectable early. Most users in performance contexts report cycles of 4-8 weeks.
Long-term human safety data for IGF-1 LR3 does not exist. Native IGF-1 (mecasermin) long-term use has been associated with various adverse effects including tonsillar hypertrophy and potential cancer risk concerns.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate IGF-1 LR3 product quality
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (6 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining IGF-1 LR3 with other peptides. Based on published research and mechanistic considerations.
Hgh
SynergisticHGH stimulates endogenous IGF-1 production. Adding exogenous IGF-1 LR3 may amplify anabolic effects but also compounds risks including hypoglycemia and potential cancer promotion.
Mgf
CompatibleMGF (Mechano Growth Factor) is an IGF-1 splice variant. Different kinetics and localization may provide complementary effects, but combined safety is not established.
BPC-157
CompatibleDifferent regenerative mechanisms - BPC-157 for tissue healing, IGF-1 LR3 for muscle growth. Theoretical complementary use.
TB-500
CompatibleTB-500 promotes tissue repair via actin regulation while IGF-1 LR3 drives muscle hypertrophy. Different mechanisms may be complementary.
Insulin
CautionBoth cause hypoglycemia through different mechanisms. Combined use dramatically increases risk of severe hypoglycemia.
Igf-1
AvoidBoth act on the same receptor. Combining provides no additional benefit and increases risk of hypoglycemia and other adverse effects.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare IGF-1 LR3
IGF-1 LR3 Calculators
Related Peptides
CJC-1295
DAC:GRF, Modified GRF 1-29, Tetrasubstituted GRF
A synthetic analog of growth hormone-releasing hormone (GHRH) with extended half-life. Limited clinical development; not approved for any indication.
Follistatin
FST, FS-344, FS-315 +1 more
An endogenous glycoprotein that inhibits myostatin and activin signaling, potentially allowing muscle growth beyond genetic limits. Gene therapy trials for muscular dystrophy show promise, but injectable peptide forms remain unapproved and understudied in humans.
GHRP-2
Growth Hormone Releasing Peptide-2, Pralmorelin, KP-102
A synthetic hexapeptide GH secretagogue with the strongest GH-releasing potency in its class. More potent than GHRP-6 with different side effect profile: less appetite stimulation but greater cortisol and prolactin elevation. Approved in Japan as Pralmorelin for GH deficiency diagnosis. Extensively studied in human pharmacology with robust clinical data.
GHRP-6
Growth Hormone Releasing Peptide-6, SKF-110679, Growth Hormone-Releasing Hexapeptide
A first-generation growth hormone secretagogue that stimulates GH release through the ghrelin receptor. Less selective than newer alternatives with effects on cortisol and prolactin. Historically significant as the peptide that led to ghrelin discovery. Cuban CIGB leads global cytoprotective research. Not approved for any indication.
Human Chorionic Gonadotropin (hCG)
hCG, Choriogonadotropin, Pregnyl +5 more
A glycoprotein hormone FDA-approved for ovulation induction, cryptorchidism, and hypogonadotropic hypogonadism. Functions as an LH receptor agonist with over 50 years of clinical use in reproductive medicine. Gold standard trigger for assisted reproductive technology.
Hexarelin
Examorelin, HEX, Growth Hormone Releasing Hexapeptide +2 more
The most potent synthetic GHRP (Growth Hormone Releasing Peptide), a hexapeptide that strongly stimulates GH release via the ghrelin receptor. Notable for cardioprotective effects independent of GH release. Development discontinued due to rapid desensitization with repeated dosing. Italian research leads global investigation.